Orchid Pharma rallied 5.76% to Rs 1,217.20 after the company has received an approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Exblifep(Cefepime and Enmetazobactam injections).
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.